1 – 3 of 3
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
evoke and evoke+ : design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease
Cummings, Jeffrey L. ; Atri, Alireza ; Feldman, Howard H. ; Hansson, Oskar LU
; Sano, Mary
; Knop, Filip K.
; Johannsen, Peter
; León, Teresa
and Scheltens, Philip
(2025)
In Alzheimer's Research and Therapy
17(1).
- Contribution to journal › Article
- 2024
-
Mark
Progression analysis versus traditional methods to quantify slowing of disease progression in Alzheimer’s disease
Jönsson, Linus ; Ivkovic, Milana ; Atri, Alireza ; Handels, Ron ; Gustavsson, Anders ; Hahn-Pedersen, Julie Hviid ; León, Teresa ; Lilja, Mathias ; Gundgaard, Jens and Raket, Lars Lau LU
(2024)
In Alzheimer's Research and Therapy
16(1).
- Contribution to journal › Article
-
Mark
Baseline Characteristics from Evoke and Evoke+ : Two Phase 3 Randomized Placebo-controlled Trials of Oral Semaglutide in Patients with Early Alzheimer's Disease (P11-9.013)
Scheltens, Philip ; Atri, Alireza ; Feldman, Howard ; Hansson, Oskar LU
; Knop, Filip
; Sano, Mary
; Dethlefsen, Claus
; Johannsen, Peter
; León, Teresa
and Hansen, Charlotte Thim
, et al.
(2024)
In Neurology
102(7, Suppl 1).
- Contribution to journal › Published meeting abstract